Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CASP3 | P42574 | 4/20 | 0.49 |
| ▸ | MDM4 | O15151 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.44 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670140 | 0.91 | CASP3 (0.50) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL18211250 | 0.87 | MDM2 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL29829361 | 0.84 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL19966789 | 0.83 | KMT2A (0.44) | KMT2AEPHX2 | |
| SCHEMBL16294410 | 0.83 | CASP3 (0.59) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL16294412 | 0.83 | CASP3 (0.59) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL19927329 | 0.83 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL19927331 | 0.83 | CASP3 (0.48) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL2465375 | 0.83 | EPHX2 (0.62) | KMT2ACASP3MDM4TP53EPHX2 | |
| SCHEMBL23466663 | 0.82 | KLKB1 (0.52) | PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487520-B2 | Coelenterazine derivatives and methods of using same | PROMEGA CORPORATION (US) | 2016-11-08 | — | — | US | disclosed |
| EP-2635583-B1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | PROMEGA CORP (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2635583-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | Promega Corporation (US) | 2013-09-11 | — | — | EP | disclosed |
| WO-2012061477-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | PROMEGA CORPORATION (US) | 2012-05-10 | — | — | WO | disclosed |
| US-20120107849-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120107849-A1 | COELENTERAZINE DERIVATIVES AND METHODS OF USING SAME | SI, CNDP2, PEPD | KMT2A 2505/4885CASP3 1684/4885MDM4 3871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.